Untreated Childhood Brain Stem Glioma
7
0
0
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
14.3%
1 terminated out of 7 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
100%
5 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Tipifarnib and Radiation Therapy in Treating Young Patients With Brainstem Glioma
Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma